Spyglass Pharma, Inc. (NASDAQ:SGP – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $28.22, but opened at $29.21. Spyglass Pharma shares last traded at $29.25, with a volume of 3,202 shares trading hands.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Raymond James Financial started coverage on Spyglass Pharma in a report on Friday, August 14th. They issued an “outperform” rating and a $39.00 price target on the stock. UBS Group restated a “buy” rating on shares of Spyglass Pharma in a research report on Monday, October 5th. Weiss Ratings lowered shares of Spyglass Pharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, September 25th. Wall Street Zen cut shares of Spyglass Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 price target on shares of Spyglass Pharma in a research note on Wednesday, October 21st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.00.
Check Out Our Latest Stock Analysis on Spyglass Pharma
Spyglass Pharma Price Performance
Spyglass Pharma (NASDAQ:SGP – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). On average, sell-side analysts expect that Spyglass Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.
Institutional Trading of Spyglass Pharma
A number of large investors have recently made changes to their positions in SGP. Bank of New York Mellon Corp bought a new position in Spyglass Pharma during the second quarter worth about $533,000. Bank of America Corp DE acquired a new stake in shares of Spyglass Pharma during the first quarter worth about $726,000. First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma during the first quarter worth about $9,716,000. Affinity Asset Advisors LLC bought a new position in shares of Spyglass Pharma during the 1st quarter valued at about $6,478,000. Finally, Monashee Investment Management LLC bought a new position in shares of Spyglass Pharma during the 1st quarter valued at about $2,461,000.
Spyglass Pharma Company Profile
SpyGlass Pharma, Inc is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company’s platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.
SpyGlass Pharma’s lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.
The company is advancing its technology through clinical development and regulatory processes in the United States.
Further Reading
- Five stocks we like better than Spyglass Pharma
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
Receive News & Ratings for Spyglass Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyglass Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
